Variations of serum testosterone levels in prostate cancer patients under LH-releasing hormone therapy: an open question
Endocrine-Related Cancer, Exclusive Author Commentary

Reis LO – In the last few years and months, important advancements in prostate cancer treatment have been achieved. Nevertheless, these advances are measured in a few months of additional survival and under high costs, not available to most of the world population, compared with the benefits of hormonal manipulation that are measured in years, there is a huge potential for accessible and durable effect expansion and optimization of treatment, particularly with the current tendency of a more individual approach.

Variations of serum testosterone levels in prostate cancer patients under LH-releasing hormone therapy: an open question Leonardo Oliveira Reis, MD, MSc, PhD Found at The equivalence of surgical and different pharmacological castrations has been contested, and it is of concern that most of the phase III studies for the Food and Drug Administration licensing of LHRH agonists were based on the previous 50 ng/dl castration level defined by the historical assay limitation, dated before 1996. Adding to this controversy is a cluster of evidence supporting the hypothesis ‘the lower the better when achieving castration levels of testosterone’, based on the data from second-line hormonal manipulation and its molecular basis [1]. Until now, the optimal serum testosterone level in patients under castration and the impact of its variations in patients under LHRH therapy remain uncertain. In the current scenario of advancements measured in a few months and under high costs, which are not available to most of the world population, compared with the benefits of hormonal manipulation that are measured in years [1], this denotes a huge potential for accessible and durable effect expansion and optimization of treatment, particularly for the current tendency of a more individual approach. We have previously highlighted [1] that although the androgen receptor (AR) is the major therapeutic target of prostate cancer (PCa), there are currently no clinical studies available in which the AR status was considered in the study design. Furthermore, to date, even with better understanding of the molecular pathways behind castration resistant prostate cancer (CRPC), no study on secondary hormonal treatment with strong methodology has shown a benefit in terms of survival, but most trials have been smaller and heavily biased for patients’ heterogeneity. Adding to this complex and challenging scenario is the fact recently confirmed by our group that the efficiency of the different available pharmacological castration solutions aimed at reaching castration levels, mainly for cutoff ? 20 ng/dl, can vary significantly; surprisingly, about half and one-third of patients did not achieve castration levels of 20 and 50 ng/dl respectively [2]. It is of concern that although in the last 2 years, three approved treatments based on Phase III trials have demonstrated modest survival improvements (measured in months) in CRPC [cabazitaxel (potent taxane able to bypass the main resistance mechanism to docetaxel drug efflux pump, P-glycoprotein 1; approved in 2010); sipuleucel-T (immunotherapeutic agent through dendritic cells; approved in 2010); and abiraterone (orally active, potent and irreversible inhibitor of CYP17 – a critical enzyme in androgen biosynthesis; approved in 2011)], palpable advancement in hormonal management has been scarce and underexplored [1,2]. The sequential responses to hormonal manipulation, known as secondary hormonal therapy, implies that AR signaling remains an important therapeutic target and also relies on the fact that CRPC is not necessarily androgen-independent and is susceptible to further hormonal manipulation [1]. Although an imperative clinical consideration, ineffective testosterone suppression (ITS) through hormonal escape is not recognized when serum testosterone is not systematically monitored, culminating in very scarce data analyzing the impact of serum testosterone levels and breakthrough increases in PCa clinical outcome. Abiraterone, effectively blocking the conversion of androgens from non-gonadal precursors, thus reducing testosterone to undetectable levels, has recently been proved to extend survival rates for men with metastatic CRPC who have progressive disease even after first-line chemotherapy treatment [1]. Furthermore, when defining CRPC, the specific hormone therapy administered and the response to that therapy can influence the biology of the relapsing tumor and the sensitivity to subsequent therapies, and are therefore fundamental predictors of survival in individual patients. There are unquestionably different molecular determinants on why one cancer would respond to possibly slightly higher androgen levels than another, and this presumably relates to how the AR is working. Current literature on the issue must be interpreted cautiously once they are not designed based on the above-mentioned rational and does not take into consideration the molecular basis, being obviously not powered to detect small differences in outcome, owing to patients’ heterogeneity and the relatively short median follow-up. Future studies must be based on the proposed rational, with the accurate design of a more individual approach with precise molecular targets, and very long follow-up periods, combined with well-defined and accurate oncological and survival primary outcomes. References: 1- Reis LO 2011 Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum. Medical Oncology [in press]. (doi:10.1007/s12032-011- 9991-z;PMID:21626233) 2- Silva ED, Ferreira U, Matheus W, Faria EF, Silva GD, Saito M, de Souza AA, Laranjo A Jr, Clark O, Magna LA, Castilho LN, Reis LO. 2012 Goserelin versus leuprolide in the chemical castration of patients with prostate cancer. International Urology and Nephrology [in press]. (doi:10.1007/s11255-012-0134-z;PMID:22315155) Prof. Dr. Leonardo Oliveira Reis, MD, MSc, PhD Department of Surgery (Urology),?School of Medical Sciences,?University of Campinas, UNICAMP, Brazil. Professor?of Medicine (Urology),?Center for Life Sciences,?Pontifical Catholic University of Campinas,?PUC-Campinas, Brazil

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Nursing

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Nursing Articles

1 Tea consumption and leukemia risk: A meta-analysis Tumor Biology, February 12, 2014    Evidence Based Medicine    Clinical Article

2 Effect of a low-flatulogenic diet in patients with flatulence and functional digestive symptoms Neurogastroenterology & Motility, February 25, 2014    Clinical Article
Exclusive Author Commentary

3 Egg consumption and insulin metabolism in the Insulin Resistance Atherosclerosis Study (IRAS) Public Health Nutrition, June 24, 2014    Clinical Article

4 Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis American Journal of Clinical Nutrition, June 4, 2014    Evidence Based Medicine    Review Article

5 Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: An open-label randomized controlled pilot study Clinical Journal of the American Society of Nephrology, May 23, 2014    Clinical Article

6 Long-term associations of nut consumption with body weight and obesity American Journal of Clinical Nutrition, June 23, 2014    Clinical Article

7 Yogurt consumption and impact on health: focus on children and cardiometabolic risk American Journal of Clinical Nutrition, March 21, 2014    Review Article

8 Fruits and vegetables consumption and risk of stroke Stroke, May 28, 2014    Evidence Based Medicine

9 A review of the effects of nuts on appetite, food intake, metabolism, and body weight American Journal of Clinical Nutrition, June 26, 2014    Review Article

10 Consumption of fruits, vegetables, and seaweeds (sea vegetables) and pancreatic cancer risk: The Ohsaki Cohort Study Cancer Epidemiology, May 5, 2014    Clinical Article

11 Tea, coffee, and caffeine and early-onset basal cell carcinoma in a case–control study European Journal of Cancer Prevention, June 5, 2014    Clinical Article

12 Prognostic markers of sarcoidosis: An analysis of patients from everyday pneumological practice The Clinical Respiratory Journal, May 14, 2014    Clinical Article

13 Coffee consumption and prostate cancer risk: An updated meta-analysis Cancer Causes and Control, March 3, 2014    Evidence Based Medicine    Clinical Article

14 Meta-analysis of prospective studies on the effects of nut consumption on hypertension and type 2 diabetes mellitus Journal of Diabetes, June 10, 2014    Evidence Based Medicine

15 Fish consumption, sleep, daily functioning, and heart rate variability Journal of Clinical Sleep Medicine, June 12, 2014    Clinical Article

16 Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis American Journal of Clinical Nutrition, June 19, 2014    Evidence Based Medicine    Review Article

17 High-dose vitamin D supplementation and measures of insulin sensitivity in polycystic ovary syndrome: A randomized, controlled pilot trial Fertility and Sterility, May 6, 2014    Clinical Article

18 Suicide mortality in relation to dietary intake of n-3 and n-6 polyunsaturated fatty acids and fish: Equivocal findings from 3 large US cohort studies American Journal of Epidemiology, May 12, 2014    Clinical Article

19 Antibiotic prophylaxis for ED patients with simple hand lacerations: a feasibility randomized controlled trial The American Journal of Emergency Medicine, May 19, 2014    Clinical Article

20 Low vitamin D levels linked to disease in two big studies The New York Times, April 2, 2014

Indexed Journals in Nursing: Journal of Advanced Nursing, Journal of Clinical Nursing, Nurse Education In Practicemore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More